Recombinant protein · Protein replacement · developed by Spruce Biosciences
Tralesinidase alfa is a sterile solution given by intracerebroventricular (ICV) infusion. It is studied in mucopolysaccharidosis III (MPS IIIB).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07579910 | Phase 3 | MPS IIIB | Not yet recruiting | SPRB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MPS IIIB
Updated Nov 1, 2026. Something wrong or missing? Report it on the SPRB page.
See SPRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SPRB catalysts and pipeline →